Leukemia Therapeutics Market (Types - Myeloid Leukemia, Acute Myeloid Leukemia, Chronic Lymphatic Leukemia, Acute Leukemia, Acute Lymphatic Leukemia, Chronic Leukemia, and Other Types; Therapies - Chemotherapy, Targeted Therapy, Stem Cell Therapy, Radiation Therapy, and Biological Therapy): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

A recent report published by Infinium Global Research on leukemia therapeutics market provides an in-depth analysis of segments and sub-segments in the global as well as regional leukemia therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional leukemia therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global leukemia therapeutics market. According to the report, the global leukemia therapeutics market is projected to grow at a CAGR of 6.6% over the forecast period of 2019-2025.

Market Insight

Leukemia is cancer that starts in the blood-forming tissue, such as the bone marrow and causes large numbers of abnormal blood cells to be produced and enter the bloodstream. Leukemia therapeutics works by targeting the leukemia cells by introducing targeted antibody treatments that help the immune system recognize and attack leukemia cells. Leukemia therapeutics has 5 main therapeutic antibodies in development in which three represents new treatments for adult T cell leukemia and two targets hairy cell leukemia. Leukemia therapeutics comprises of induction therapy, consolidation therapy, and maintenance therapy. It also includes chemotherapy, radiation and stem cell transplantation. New drugs are being evaluated in clinical studies, including immunotoxins, monoclonal antibodies, nucleoside analogues, hypomethylating agents, farnesyltransferase inhibitors, alkylating agents, FMS like tyrosine kinase 3 inhibitors, and multidrug-resistant modulators.

The high occurrences of leukemia drive the demand for leukemia therapeutics during the forecast period. According to the World Health Organization, leukemia is the most common blood cancer in humans with around 0.0148% of men and 0.009% of women suffering across the globe. Furthermore, an increase in the aging population base and introduction of advanced leukemia therapies treatment are another key factors that are fueling the growth of the leukemia therapeutics market. Furthermore, technological advancement and development of new drugs and therapeutics are expected to accelerate the growth of the leukemia therapeutics market. However, the high cost required for the development and growth of new therapeutics is likely to hamper the growth of the leukemia therapeutics market. Moreover, the upcoming innovative therapeutics creates an opportunity for the growth of the leukemia therapeutics market.

Among the geographies, North America dominates the global leukemia therapeutics market owing to the rise in the number of patients with cancer, growing genetic mutation, and increased expenditure. In 2016, the American Cancer Society estimates that approximately 60,140 new leukemia cases were diagnosed in the United States. Furthermore, technological advancement, increasing patient awareness, supportive government policies in terms of incentives and investments, sophisticated healthcare infrastructure are the key factors that attribute to the largest revenue in the North America region. Europe is anticipated to hold the second position in the market due to a higher presence of products with no major patent expiration. Asia-Pacific is likely to grow rapidly due to the increasing investments in research and development for the treatment of leukemia and the growing prevalence of leukemia in countries such as Japan and India.

Segment Covered

The report on global leukemia therapeutics market covers segments such as types and therapies. On the basis of types, the sub-markets include myeloid leukemia, acute myeloid leukemia, chronic lymphatic leukemia, acute leukemia, acute lymphatic leukemia, chronic leukemia, and other types. On the basis of therapies, the sub-markets include chemotherapy, targeted therapy, stem cell therapy, radiation therapy, and biological therapy.

Companies Profiled:

The report provides profiles of the companies in the market such as CELGENE CORPORATION, Eisai Co., Ltd., Genzyme Corporation, Bristol-Myers Squibb Company, Novartis AG, Biogen, F. Hoffmann-La Roche Ltd, and GlaxoSmithKline Plc. Pfizer Inc., and Other companies.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of leukemia therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.